Known targets — ChEMBL curated mechanism
POLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PRIM1PRIM2
The experimentally established mechanism targets of Cytarabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | MTOR | P42345 | 2/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | MDM2 | Q00987 | 1/20 | 1.00 |
| ▸ | NCOA1 | Q15788 | 1/20 | 1.00 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | GMNN | O75496 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.64 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.64 |
| ▸ | THPO | P40225 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | BLM | P54132 | 1/20 | 0.64 |
| ▸ | HBB | P68871 | 1/20 | 0.64 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | CDA | P32320 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cytarabine SCHEMBL787927 | 1.00 | LMNA (1.00) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL471171 | 1.00 | LMNA (1.00) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL12202579 | 1.00 | LMNA (1.00) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL329878 | 1.00 | LMNA (1.00) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL14644972 | 1.00 | LMNA (1.00) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL23066241 | 1.00 | LMNA (1.00) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL17993618 | 1.00 | LMNA (1.00) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL14853684 | 1.00 | LMNA (1.00) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL20546595 | 1.00 | LMNA (1.00) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL15630291 | 1.00 | LMNA (1.00) | LMNAMTORTHRBMDM2NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 463 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416293-A1 | SYNTHESIS OF [18F]-LABELED THYMIDINE ANALOGUES | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2023-12-28 | — | — | US | claimed |
| WO-2022149837-A1 | ANTI-FGFR3 ANTIBODY AND USE THEREOF | (주)에임드바이오 | 2022-07-14 | — | — | WO | claimed |
| WO-2019195494-A1 | COMPOSITIONS AND METHODS FOR SYNTHESIS OF PHOSPHORYLATED MOLECULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-10-10 | — | — | WO | claimed |
| CN-110234319-A | The composition and its application method of benzamide and reactive compound | 转化药物开发有限责任公司 | 2019-09-13 | — | — | CN | claimed |
| CN-107001617-B | PEG derivative | 德鲁塔负富莱制药股份有限公司 | 2019-08-27 | — | — | CN | claimed |
| US-9540412-B2 | Methods of preparing targeted aptamer prodrugs | ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. (US) | 2017-01-10 | — | — | US | claimed |
| CN-105288648-A | Phospholipid compound of hydrophilic drugs as well as pharmaceutical composition and application of phospholipid compound | UNIV SOUTHEAST | 2016-02-03 | — | — | CN | claimed |
| EP-1912635-B1 | USE OF CHK2 KINASE INHIBITORS FOR CANCER TREATMENT | US GOV HEALTH & HUMAN SERV (US) | 2014-03-05 | — | — | EP | claimed |
| EP-2101790-A1 | COMBINATION COMPRISING CNDAC (2'-CYANO-2'-DEOXY-N4-PALMITOYL-1-BETA-D-ARABINOFURANOSYL-CYTOSINE) AND A CYTOTOXIC AGENT | Cyclacel Limited (GB) | 2009-09-23 | — | — | EP | claimed |
| US-20090136558-A1 | Anti-Restenosis Coatings and Uses Thereof | VASOTECH, INC. (US) | 2009-05-28 | — | — | US | claimed |
| WO-2008075042-A1 | COMBINATION COMPRISING CNDAC (2'-CYANO-2'-DEOXY-N4-PALMITOYL-1-BETA-D-ARABINOFURANOSYL-CYTOSINE) AND A CYTOTOXIC AGENT | CYCLACEL LIMITED (GB) | 2008-06-26 | — | — | WO | claimed |
| WO-2002043771-A9 | CONJUGATES OF GLYCOSYLATED/GALACTOSYLATED PEPTIDE | CELL WORKS INC (US) | 2004-04-29 | — | — | WO | claimed |
| EP-1355672-A2 | CONJUGATES OF GLYCOSYLATED/GALACTOSYLATED PEPTIDE, BIFUNCTIONAL LINKER, AND NUCLEOTIDIC MONOMERS/POLYMERS, AND RELATED COMPOSITIONS AND METHODS OF USE | Cell Works Inc. (US) | 2003-10-29 | — | — | EP | claimed |
| WO-2002043771-A2 | CONJUGATES OF GLYCOSYLATED/GALACTOSYLATED PEPTIDE | CELL WORKS INC. (US) | 2002-06-06 | — | — | WO | claimed |
| EP-0536936-B1 | Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use | SANKYO CO (JP) | 1996-08-14 | — | — | EP | claimed |
| EP-0536936-A1 | Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use | Sankyo Company Limited (JP) | 1993-04-14 | — | — | EP | claimed |
| EP-0409227-A2 | Pyrimidine nucleosides, their preparation and pharmaceutical preparations | MATTHES, Eckart, Dr. (DE) | 1991-01-23 | — | — | EP | claimed |
| JP-60067493-A | — | — | None | — | — | JP | disclosed |
| EP-0048022-A2 | Enhancer of anti-tumor effect | Yamasa Shoyu Kabushiki Kaisha (JP) | 1982-03-24 | — | — | EP | disclosed |
| EP-0004223-A1 | Process for the preparation of lipidic capsules containing a biologically active compound, products obtained by this process as well as their utilisation | PAPAHADJOPOULOS, Demetrios P. (US) | 1979-09-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416293-A1 | SYNTHESIS OF [18F]-LABELED THYMIDINE ANALOGUES | DCTD, DUT, RNMT | LMNA 3753/4885MTOR 4120/4885THRB 1585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.